Evaxion unveils proprietary genetic adjuvant technologies to
- Evaxion created a genetic adjuvant technologies that boosts the immune responses of viral, bacterial and cancer vaccines
- Preclinically validated for each DNA and mRNA vaccines, and prepared for clinical testing
- Anticipated significant industry prospective for DNA and mRNA vaccines against cancer, viral and bacterial illnesses
COPENHAGEN, Denmark, Could 25, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology organization specializing in the discovery and improvement of AI-powered immunotherapies, nowadays unveils the technologies behind its novel, proprietary genetic adjuvant created to improve the effectiveness of DNA and mRNA vaccines for infectious illnesses and cancer.
Most up-to-date information from the adjuvant system had been presented at Evaxion’s reside stream R&D Day, Could 25, 2023.
“We are excited to present this novel genetic adjuvant technologies to the worldwide scientific neighborhood. It boosts Evaxion´s personal DNA technologies and has the prospective to increase the impact of practically any vaccine. We foresee a terrific industry prospective in that this technologies seems to be very powerful in each DNA and mRNA primarily based vaccines against cancer as nicely as infectious illnesses,” stated Per Norlén, CEO at Evaxion.
Evaxion´s novel genetic adjuvant carries the code for CCL19, a molecule recognized to attract immune cells, notably antigen presenting cells, and can be encoded into either DNA or mRNA vaccines with the aim of boosting the immune response.
Most up-to-date information show that the genetic adjuvant technologies boosts the antitumor impact in preclinical tumor models, and induces neutralizing antibodies and T-cell responses against each viral and bacterial antigens:
Per Norlén continues, “By encoding the immune-stimulating molecule CCL19 into either DNA or mRNA vaccines, we have demonstrated considerable enhancement of the vaccines effectiveness. We think that this advancement holds immense prospective for vaccine improvement, as it boosts each B cell and T cell immune responses, producing it applicable to a wide variety of vaccines. Constructing on the encouraging preclinical final results, the subsequent step is to validate the technologies in sufferers.”
Evaxion aims to bring the genetic adjuvant technologies into clinical trials later this year as component of the customized cancer immunotherapy system EVX-03.
Please go to the Investors section of Evaxion’s web page to access a replay of the R&D Day presentations.
Evaxion Biotech A/S is a pioneering organization creating AI-powered immunotherapies. Evaxion’s proprietary and scalable AI technologies decode the human immune program to find out and create novel immunotherapies for cancer, bacterial illnesses, and viral infections. Evaxion has a broad pipeline of candidates, which includes 3 customized cancer immunotherapies. It is situated in Hørsholm, Denmark, with 50 workers listed on the Nasdaq New York stock exchange. For additional details, please go to www.evaxion-biotech.com.
This announcement includes forward-hunting statements inside the which means of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of comparable which means determine forward-hunting statements. Actual final results could differ materially from these indicated by such forward-hunting statements as a outcome of several variables, which includes, but not restricted to, dangers associated to: our monetary situation and want for added capital our improvement operate price and achievement of our solution improvement activities and preclinical and clinical trials commercializing any authorized pharmaceutical solution created making use of our AI platform technologies, which includes the price and degree of industry acceptance of our solution candidates our dependence on third parties which includes for conduct of clinical testing and solution manufacture our inability to enter into partnerships government regulation protection of our intellectual house rights employee matters and managing development our ADSs and ordinary shares, the influence of international financial, political, legal, compliance, social and small business variables, which includes inflation, and the effects on our small business from the worldwide COVID-19 pandemic and the ongoing conflict in the area surrounding Ukraine and Russia and other uncertainties affecting our small business operations and monetary situation. For a additional discussion of these dangers, please refer to the danger variables incorporated in our most current Annual Report on Type 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are readily available at www.sec.gov. We do not assume any obligation to update any forward-hunting statements except as expected by law.